MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'
April 4, 2024 4:40 AM EDTStifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).
The analyst comments "Were incrementally more positive on MGNX shares following managements disclosure of vobra-duo safety/tolerability data from the P2 TAMARACK trial contained within an... More
